What is the price target for CAI stock?
14 analysts have analysed CAI and the average price target is 32.92 USD. This implies a price increase of 55.64% is expected in the next year compared to the current price of 21.15.
NASDAQ:CAI • US1421521071
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CARIS LIFE SCIENCES INC (CAI).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-13 | Jefferies | Initiate | Buy |
| 2026-04-10 | Piper Sandler | Initiate | Neutral |
| 2026-04-06 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-03-13 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2026-02-27 | BTIG | Maintains | Buy -> Buy |
| 2026-02-27 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-27 | Baird | Maintains | Outperform -> Outperform |
| 2026-02-17 | Baird | Initiate | Outperform |
| 2025-12-22 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-12-02 | Canaccord Genuity | Initiate | Hold |
| 2025-08-13 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-13 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-08-13 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-15 | Evercore ISI Group | Initiate | Outperform |
| 2025-07-14 | TD Cowen | Initiate | Buy |
| 2025-07-14 | Guggenheim | Initiate | Buy |
| 2025-07-14 | Wolfe Research | Initiate | Outperform |
| 2025-07-14 | JP Morgan | Initiate | Overweight |
| 2025-07-14 | Citigroup | Initiate | Buy |
| 2021-06-30 | Keefe, Bruyette & Woods | Downgrade | Outperform -> Market Perform |
| 2021-06-21 | William Blair | Downgrade | Outperform -> Market Perform |
| 2021-06-18 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 306.128M -24.35% | 412.26M 34.67% | 812.033M 96.97% | 1.017B 25.24% | 1.244B 22.32% | 1.454B 16.88% | 1.633B 12.31% | 1.842B 12.80% | 1.922B 4.34% | |
| EBITDA YoY % growth | -270.55M | -208.209M 23.04% | 67.728M 132.53% | 167.18M 146.84% | 259.66M 55.32% | 350.79M 35.10% | 485.25M 38.33% | 555.55M 14.49% | 656.8M 18.23% | |
| EBIT YoY % growth | -319.551M | -257.122M 19.54% | 45.113M 117.55% | 87.902M 94.85% | 184.52M 109.92% | 266.35M 44.35% | 361.88M 35.87% | 464.63M 28.39% | 474.2M 2.06% | |
| Operating Margin | -104.38% | -62.37% | 5.56% | 8.64% | 14.83% | 18.32% | 22.16% | 25.22% | 24.67% | |
| EPS YoY % growth | N/A -18.46% | N/A -3.52% | N/A -128.65% | 0.13 106.30% | 0.37 193.11% | 0.64 72.68% | 0.73 13.64% | 0.86 18.06% | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.02 | 0.03 100.38% | 0.07 -15.46% | 0.10 -64.84% | 0.05 319.66% | 0.10 229.38% | 0.13 91.48% | 0.16 58.31% |
| Revenue Q2Q % growth | 212.39M 75.65% | 251.28M 38.52% | 263.78M 21.65% | 289.45M -1.17% | 272.53M 28.32% | 311.63M 24.02% | 317.9M 20.52% | 340.3M 17.57% |
| EBITDA Q2Q % growth | 21.534M 142.30% | 40.716M 997.82% | 51.131M 0.32% | 59.599M -46.32% | 49.126M 128.13% | 68.68M 68.68% | 79.224M 54.94% | 85.85M 44.05% |
| EBIT Q2Q % growth | -1.782M 96.92% | 16.361M 190.95% | 27.963M -14.33% | 35.824M -59.48% | 25.346M 1,522.14% | 42.583M 160.27% | 51.511M 84.21% | 56.688M 58.24% |
All data in USD
14 analysts have analysed CAI and the average price target is 32.92 USD. This implies a price increase of 55.64% is expected in the next year compared to the current price of 21.15.
The consensus EPS estimate for the next earnings of CARIS LIFE SCIENCES INC (CAI) is -0.02 USD and the consensus revenue estimate is 212.39M USD.
The expected long term growth rate for CARIS LIFE SCIENCES INC (CAI) is 5.04%.